Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Summary of the main characteristics of the six subtypes. Symbols correspond to the relative frequency within the subtype (o: very low frequencies [∼0%]; +++: very high frequencies; +/++: intermediate frequencies), and arrows indicate significant enrichment of subtype up- and down-regulated genes in most of the pathways of the given category. EMT, epithelial–mesenchymal transition; SC, stem cell; Wnt pw, Wnt pathway.](https://figures.cochat.ai/paper-figures/d9e6ea3312ee4d83b17b55c403c90fdb/gene-expression-classification-of-colon-cancer-into-molecular-subtypes-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, the MEKi bypass resistance was strongly correlated with the SRC activation/dasatinib sensitivity, the EMT-like stemness and the CMS4 subtype (see Fig. 6 and Fig. 7 as well as Additional File 3_Fig S5 and Fig S6).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar results were seen in Marisa 458 CMS1-4 CRC tumors (Fig. 8d).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“To obtain a robust classification, we used a consensus unsupervised approach [22] implemented in the R package ConsensusClusterPlus.”
MethodWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Research works printed but not linked: 1
- American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.
Cited by
Items 401–500 of 1,001
Weighted Kolmogorov Smirnov testing: an alternative for Gene Set Enrichment Analysis
Charmpi, K., & Ycart, B. (2015) · Statistical Applications in Genetics and Molecular Biology · doi:10.1515/sagmb-2014-0077 · Cited by 37
Shaping of an effective immune microenvironment to and by cancer cells
Becht, É., Goc, J., Germain, C., Giraldo, N. A., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1590-3 · Cited by 38
Berdiel‐Acer, M., Berenguer, A., Pamplona, R. S., Cuadras, D., Sanjuán, X., Paúles, M. J., Santos, C., Salazar, R., Moreno, V. R., Capellá, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2237 · Cited by 37
Zhang, X., Pan, S.-X., Wang, A., Kong, Q.-Y., Jiang, K.-T., & Yu, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.915329 · Cited by 37
The miR‐28‐5p‐CAMTA2 axis regulates colon cancer progression via Wnt/β‐catenin signaling
Luan, X., Wang, L., & Gai, X. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29536 · Cited by 38
Foroutan, M., Molania, R., Pfefferle, A., Behrenbruch, C., Scheer, S., Kallies, A., Speed, T. P., Cursons, J., & Huntington, N. D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0137 · Cited by 37
Wang, W., Xu, C., Ren, Y., Wang, S., Liao, C., Fu, X., & Hu, H. (2021) · Stem Cells International · doi:10.1155/2021/7036059 · Cited by 37
Ma, B., Wang, K., Yu, L., Meng, Q., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809837 · Cited by 37
Kwok, H. F., Zhang, S., McCrudden, C. M., Chen, M., & Lin, Y. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s80518 · Cited by 37
Care, M. A., Westhead, D. R., & Tooze, R. M. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0090-7 · Cited by 39
Sáenz‐de‐Santa‐María, I., Celada, L., & Chiara, M. (2020) · Cells · doi:10.3390/cells9030731 · Cited by 37
Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2403 · Cited by 36
Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification
Sreekumar, R., Harris, S., Moutasim, K. A., DeMateos, R., Patel, A., Emo, K., White, S., Yağcı, T., Tulchinsky, E. M., Thomas, G. J., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3115 · Cited by 36
Ozawa, T., Hashiguchi, Y., Yagi, T., Fukushima, Y., Shimada, R., Hayama, T., Tsuchiya, T., Nozawa, K., Iinuma, H., Ishihara, S., et al. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03379-y · Cited by 36
Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival
Yang, Y., Shi, Z. Q., Bai, R., & Hu, W. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106609 · Cited by 36
Wang, Y., Li, W., Jin, X., Jiang, X., Guo, S., Xu, F., Su, X., Wang, G., Zhao, Z., & Gu, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08629-3 · Cited by 36
Identifying Novel Actionable Targets in Colon Cancer
Cerrito, M. G., & Grassilli, E. (2021) · Biomedicines · doi:10.3390/biomedicines9050579 · Cited by 37
Yang, C., Cao, F., Huang, S., & Zheng, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717505 · Cited by 36
KCTD9 Inhibits the Wnt/β-Catenin Pathway by Decreasing the Level of β-Catenin in Colorectal Cancer
Yao, H., Ren, D., Wang, Y., Wu, L., Wu, Y., Wang, W., Li, Q., & Liu, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05200-1 · Cited by 36
Semlali, A., Amri, A. A., Azzi, A., Alshahrani, O. M., Arafah, M., Kohailan, M., Aljebreen, A., Alharbi, O., Almadi, M. A., Azzam, N. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126868 · Cited by 36
Implications of Epithelial–Mesenchymal Plasticity for Heterogeneity in Colorectal Cancer
Pereira, L. A., Mariadason, J. M., Hannan, R. D., & Dhillon, A. S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00013 · Cited by 36
Overexpression of miRNA-143 Inhibits Colon Cancer Cell Proliferation by Inhibiting Glucose Uptake
Zhao, J., Chen, Y., Liu, F., & Yin, M. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.12.009 · Cited by 36
Impact of Fibroblast-Derived SPARC on Invasiveness of Colorectal Cancer Cells
Drev, D., Harpain, F., Beer, A., Stift, A., Gruber, E. S., Klimpfinger, M., Thalhammer, S., Réti, A., Kenner, L., Bergmann, M. M., et al. (2019) · Cancers · doi:10.3390/cancers11101421 · Cited by 36
Peters, N. A., Constantinides, A., Ubink, I., van Kuik, J., Bloemendal, H. J., van Dodewaard, J. M., Brink, M. A., Schwartz, T. P., Lolkema, M. P. J. K., Lacle, M. M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969855 · Cited by 35
Integrated analysis of long non-coding RNAs in human colorectal cancer
Chen, X., Liu, B., Yang, R., Guo, Y., Li, F., Wang, L., & Hu, H. (2016) · Oncotarget · doi:10.18632/oncotarget.8192 · Cited by 35
Image-based surrogate biomarkers for molecular subtypes of colorectal cancer
Popovici, V. C., Budínská, E., Dušek, L., Kozubek, M., & Bosman, F. T. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx027 · Cited by 35
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 35
Eskandari, E., Mahjoubi, F., & Motalebzadeh, J. (2018) · Gene · doi:10.1016/j.gene.2018.09.003 · Cited by 35
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2019) · Aging · doi:10.18632/aging.102349 · Cited by 35
Buechler, S. A., Stephens, M., Hummon, A. B., Ludwig, K. R., Cannon, E. E., Carter, T. C., Resnick, J. M., Gökmen‐Polar, Y., & Badve, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-69083-y · Cited by 35
A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models
Hsiao, Y.-W., Tao, C.-L., Chuang, E. Y.-Y., & Lu, T. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.11.006 · Cited by 35
Dissecting cancer heterogeneity – An unsupervised classification approach
Wang, X., Markowetz, F. M., Melo, F. D. S. E., Medema, J. P., & Vermeulen, L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.08.014 · Cited by 35
CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer
Nguyen, M. N., Choi, T. G., Nguyen, D. T., Kim, J. H., Jo, Y. H., Shahid, M., Akter, S., Aryal, S. N., Yoo, J. Y., Ahn, Y.-J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5183 · Cited by 35
Ke, H., Li, Z., Li, P., Ye, S., Huang, J., Hu, T., Zhang, C., Yuan, M., Chen, Y., Wu, X., et al. (2022) · Gastroenterology report · doi:10.1093/gastro/goad034 · Cited by 34
Borovski, T., Vellinga, T. T., Laoukili, J., Santo, E. E., Fátrai, S., van Schelven, S., Verheem, A., Marvin, D. L., Ubink, I., Rinkes, I. H. M. B., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311547 · Cited by 34
Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis
Ma, S., Ogino, S., Parsana, P., Nishihara, R., Qian, Z., Shen, J., Mima, K., Masugi, Y., Cao, Y., Nowak, J. A., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1511-4 · Cited by 34
L1TD1 - a prognostic marker for colon cancer
Chakroborty, D., Emani, M., Klén, R., Böckelman, C., Hagström, J., Haglund, C. H., Ristimaki, A. P., Lahesmaa, R., & Elo, L. L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5952-2 · Cited by 34
KRT17 as a prognostic biomarker for stage II colorectal cancer
Ujiie, D., Okayama, H., Saito, K., Ashizawa, M., Min, A. K. T., Endo, E., Kase, K., Yamada, L., Kikuchi, T., Hanayama, H., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz192 · Cited by 34
Jin, L., Li, C., Liu, T., & Wang, L. (2020) · Human Genomics · doi:10.1186/s40246-020-00270-8 · Cited by 34
Lv, K., Li, R., Cao, Y., Gu, Y., Liu, X., He, X., Jin, K., Fang, H., Fei, Y., Shi, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33358 · Cited by 34
Yang, C., Huang, S., Cao, F., & Zheng, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08902-5 · Cited by 34
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
Crawford, N., Stott, K. J., Sessler, T., McCann, C. K., McDaid, W. J., Lees, A., Latimer, C. H., Fox, J. P., Munck, J. M., Smyth, T., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1050 · Cited by 34
Ren, Y., He, S., Feng, S., & Yang, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.916364 · Cited by 34
Pastorino, G. A., Sheraj, I., Huebner, K., Ferrero, G., Kunze, P., Hartmann, A., Hampel, C., Hüsnügil, H. H., Maiuthed, A., Gebhart, F., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6240 · Cited by 35
Győrffy, B., Stelniec‐Klotz, I., Sigler, C., Kasack, K., Redmer, T., Yu, Q., & Schäfer, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3871 · Cited by 34
Dekervel, J., Hompes, D., van Malenstein, H., Popovic, D. D., Sagaert, X., Moor, B. D., Cutsem, E. V., D’Hoore, A. J. L., Verslype, C., & van Pelt, J. F. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2958 · Cited by 34
Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
Duex, J. E., Owens, C. R., Chauca-Diaz, A., Dancik, G. M., Vanderlinden, L. A., Ghosh, D., Leivo, M. Z., Hansel, D. E., & Theodorescu, D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0367 · Cited by 34
Huang, C., Wu, S., Li, W., Herkilini, A., Miyagishi, M., Zhao, H., & Kasim, V. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.070 · Cited by 34
Buikhuisen, J. Y., Gomez Barila, P. M., Torang, A., Dekker, D., de Jong, J. H., Cameron, K., Vitale, S., Stassi, G., van Hooff, S. R., Castro, M. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13040801 · Cited by 33
“In the top-ranking associated genes one gene stood out as it is one of the top centroid genes for a poor prognosis mesenchymal subtype of CRC [7] and was previously shown to be selectively expressed within the epithelial compartment of CRC [14,53].”
BackgroundAulas, A., Finetti, P., Lyons, S. M., Bertucci, F., Birnbaum, D., Acquaviva, C., & Mamessier, É. (2020) · Cancers · doi:10.3390/cancers12092470 · Cited by 33
Wang, X., Liu, J., Wang, D., Feng, M., & Wu, X.-Z. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa309 · Cited by 33
Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer
Andrijes, R., Hejmadi, R. K., Pugh, M., Rajesh, S., Novitskaya, V., Ibrahim, M., Overduin, M., Tselepis, C., Middleton, G., Győrffy, B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011411118 · Cited by 33
Chen, G. T., Tifrea, D. F., Murad, R., Habowski, A. N., Lyou, Y., Duong, M. R., Hosohama, L., Mortazavi, A., Edwards, R. A., & Waterman, M. L. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0349 · Cited by 33
Wu, Q., Huang, Q., Jiang, Y., Sun, F., Liang, B., Wang, J., Hu, X., Sun, M., Ma, Z., Shi, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0124 · Cited by 33
β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Suzuki, T., Kilbey, A., Casa-Rodríguez, N., Lawlor, A., Γεωργακοπούλου, Α., Hayman, H., Swe, K. L. Y., Nordin, A., Cantù, C., Vantourout, P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0644 · Cited by 33
Linking gene expression to phenotypes via pathway information
Papatheodorou, I., Oellrich, A., & Smedley, D. P. (2015) · Journal of Biomedical Semantics · doi:10.1186/s13326-015-0013-5 · Cited by 33
Sztupinszki, Z. M., & Győrffy, B. (2016) · Scientific Reports · doi:10.1038/srep37169 · Cited by 33
A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer
Sho, S., Court, C. M., Winograd, P., Russell, M. M., & Tomlinson, J. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24781 · Cited by 33
Independent prognostic genes and mechanism investigation for colon cancer
Li, C., Shen, Z., Zhou, Y., & Yu, W. (2018) · Biological Research · doi:10.1186/s40659-018-0158-7 · Cited by 33
Molecular Insights Into Colorectal Carcinoma
Requena, D. O., & Garcia-Buitrago, M. T. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.09.014 · Cited by 33
Intrinsic cancer subtypes-next steps into personalized medicine
Santos, C., Pamplona, R. S., Nadal, E., Grasselli, J., Pernas, S., Dienstmann, R., Moreno, V. R., Tabernero, J. M., & Salazar, R. (2015) · Cellular Oncology · doi:10.1007/s13402-014-0203-7 · Cited by 34
Huang, R., Zhou, L., Chi, Y., Wu, H., & Shi, L. (2020) · Biomarker Research · doi:10.1186/s40364-020-00187-3 · Cited by 32
Li, W., Herkilini, A., Tang, Y. R., Huang, P. C., Song, G., Miyagishi, M., Kasim, V., & Wu, S. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00599-9 · Cited by 32
Liu, J., Jiang, C., Xu, C., Wang, D., Shen, Y., Liu, Y., & Gu, L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01795-1 · Cited by 32
Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management
Hassan, S., Shehzad, A., Khan, S. A., Miran, W., Khan, S., & Lee, Y. S. (2022) · Biomedicines · doi:10.3390/biomedicines10082047 · Cited by 32
Advances in immunotyping of colorectal cancer
Wu, Y., Jing, Z., Qu, Z., Yang, X., & Han, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259461 · Cited by 32
Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Sakuma, M., Fukai, S., Endo, E., Sakamoto, W., Saito, M., et al. (2023) · Cancers · doi:10.3390/cancers15204943 · Cited by 32
Wu, R., Nie, Q., Tapper, E. E., Jerde, C. R., Dunlap, G. S., Shrestha, S., Elraiyah, T. A., Offer, S. M., & Diasio, R. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1306 · Cited by 32
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Jaramillo-Koupermann, G., Cáceres, Á. L., Intriago-Baldeón, D. P., García-Cárdenas, J. M., Guevara‐Ramírez, P., Armendáriz‐Castillo, I., Leone, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0102-4 · Cited by 32
Langerud, J., Eilertsen, I. A., Moosavi, S. H., Klokkerud, S. M. K., Reims, H. M., Backe, I. F., Hektoen, M., Sjo, O. H., Jeanmougin, M., Tejpar, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48706-2 · Cited by 32
Dang, Q., Zuo, L., Hu, X., Zhou, Z., Chen, S., Liu, S., Ba, Y., Zuo, A., Xu, H., Weng, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70041 · Cited by 32
Yang, Y., Wang, D., Jin, L., Wu, G., Bai, Z., Wang, J., Yao, H., & Zhang, Z. (2018) · Cancer Management and Research · doi:10.2147/cmar.s169649 · Cited by 31
Current Advances and Trends in KRAS Targeted Therapies for Colorectal Cancer
Teo, M. Y. M., Fong, J. Y., Lim, W. M., & In, L. L. A. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0248 · Cited by 31
Retinoic acid signaling drives differentiation toward the absorptive lineage in colorectal cancer
Wester, R. A., van Voorthuijsen, L., Neikes, H. K., Dijkstra, J. J., Lamers, L. A., Frölich, S., van der Sande, M., Logie, C., Lindeboom, R. G. H., & Vermeulen, M. (2021) · iScience · doi:10.1016/j.isci.2021.103444 · Cited by 31
Kim, S., Kim, S., Kim, C. W., Roh, S. A., Ha, Y. J., Lee, J. L., Heo, H., Cho, D., Lee, J., Kim, Y. S., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0319-y · Cited by 30
Tang, Y., Chen, T., Zhang, Y., Zhao, X., Zhang, Y., Wang, G., Huang, M., Cai, S., Zhao, J., Wei, B., et al. (2019) · Gastroenterology report · doi:10.1093/gastro/goaa045 · Cited by 30
Chen, Y., Luo, S.-N., Dong, L., Liu, T., Shen, X., Zhang, N., & Liang, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03054-3 · Cited by 30
Beksaç, K., Beksaç, M., Dalva, K., Karaağaoğlu, E., & Tirnaksiz, M. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132526 · Cited by 30
Lu, Y., Chen, W., Zhu, J., CHEN, W.-X., & Chen, N. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4800 · Cited by 30
Wang, F., Yan, Z., Lv, J., Xin, J., Dang, Y., Sun, X., An, Y., Qi, Y., Jiang, Q., Zhu, W., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.013 · Cited by 31
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
Abbott, J. M., Zhou, Q., Esquer, H., Pike, L. A., Broneske, T. P., Rinaldetti, S. L., Abraham, A. D., Ramirez, D. A., Lunghofer, P. J., Pitts, T. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0106 · Cited by 30
Kim, Y., Kim, D., Cao, B., Carvajal, R., & Kim, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03633-z · Cited by 30
Hong, Q., Li, B., Cai, X., Lv, Z., Cai, S., Zhong, Y., & Wen, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704531 · Cited by 30
Oshi, M., Huyser, M. R., Le, L. M., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2021) · Cancers · doi:10.3390/cancers13061477 · Cited by 29
Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature
Fakhri, B., & Lim, K. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.01 · Cited by 29
Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia
Bashir, B., Merlino, D. J., Rappaport, J. A., Gnass, E. D., Palazzo, J., Feng, Y., Fearon, E. R., Snook, A. E., & Waldman, S. A. (2019) · Human Pathology · doi:10.1016/j.humpath.2018.11.032 · Cited by 29
Bover, A. G., Hernández‐López, R., Alorda-Clara, M., de la Rosa, J. M. I., Falcó, E., Fernández, T., Torrens‐Mas, M., Roca, P., Oliver, J., Sastre‐Serra, J., et al. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105698 · Cited by 29
Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse
Kamal, Y., Dwan, D., Hoehn, H. J., Pamplona, R. S., Alonso, M. H., Moreno, V. R., Cheng, C., Schell, M. J., Kim, Y., Felder, S. I., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1862529 · Cited by 29
A Ferroptosis-Related Gene Signature Identified as a Novel Prognostic Biomarker for Colon Cancer
Qi, X., Wang, R., Lin, Y., Yan, D., Zuo, J., Chen, J., & Shen, B. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.692426 · Cited by 29
Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
Fichtner, M., Bozkurt, E., Salvucci, M., McCann, C., McAllister, K. A., Halang, L., Düssmann, H., Kinsella, S., Crawford, N., Sessler, T., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03232-z · Cited by 28
Mo, X., Su, Z., Yang, B., Zeng, Z., Lei, S., & Qiao, H. (2019) · Oncology Letters · doi:10.3892/ol.2019.11073 · Cited by 28
Miao, Y., Zhang, H., Su, B., Wang, J., Quan, W., Li, Q., & Mi, D. (2021) · PeerJ · doi:10.7717/peerj.11219 · Cited by 28
Yang, G., Yu, X., Weisenberger, D. J., Lü, T., & Liang, G. (2023) · Cancers · doi:10.3390/cancers15112934 · Cited by 28
IκB kinase‐α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage‐based anticancer therapy
Pecharromán, I., Solé, L., Villanueva, D. A., Lobo‐Jarne, T., Alonso‐Marañón, J., Bertran, J., Guillén, Y., Montoto, Á., Martínez‐Iniesta, M., García‐Hernández, V., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2023114719 · Cited by 28
Brzozowa-Zasada, M., Wyrobiec, G., Kołodziej, I., Sitarski, M., Matysiak, N., Reichman-Warmusz, E., Żaba, M., & Wojnicz, R. (2015) · Gastroenterology Review · doi:10.5114/pg.2014.47502 · Cited by 28
Bigagli, E., Filippo, C. D., Castagnini, C., Toti, S., Acquadro, F., Giudici, F., Fazi, M., Dolara, P., Messerini, L., Tonelli, F., et al. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0299-z · Cited by 28
Downregulation of lncRNA AWPPH inhibits colon cancer cell proliferation by downregulating GLUT‑1
Bai, J., Xu, J., Zhao, J., & Zhang, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10515 · Cited by 28
Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt
Dutton, L. R., Hoare, O., McCorry, A. M. B., Redmond, K. L., Adam, N. E., Canamara, S., Bingham, V., Mullan, P. B., Lawler, M., Dunne, P. D., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27050 · Cited by 28
Dashti, H., Dehzangi, A., Bayati, M., Breen, J., Lovell, N., Ebrahimi, D., Rabiee, H. R., & Alinejad‐Rokny, H. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04652-8 · Cited by 28
Jonchère, V., Marisa, L., Greene, M., Virouleau, A., Buhard, O., Bertrand, R., Svrcek, M., Cervera, P., Goloudina, A. R., Guillerm, E., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.06.002 · Cited by 28
Self-citation
Metadata
- Authors
- Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., Parc, Y., Olschwang, S., Milano, G., Laurent-Puig, P., & Boige, V.
- Affiliations
- Inserm (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- La Ligue Contre le Cancer (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hôpital Européen Georges-Pompidou (FR)
- CHU Dijon Bourgogne (FR)
- Institut Gustave Roussy (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e1001453
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3660251
- OpenAlex
- W2154941270
- Cited by
- 1,507
- References
- 40
- Citations by year
- 2026: 84 · 2025: 111 · 2024: 108 · 2023: 142 · 2022: 145 · 2021: 194 · 2020: 131 · 2019: 126 · 2018: 131 · 2017: 108 · 2016: 90 · 2015: 74 · 2014: 53 · 2013: 8
- FWCI
- 56.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- colon cancer, molecular subtypes, gene expression signatures, mismatch repair deficiency, chromosomal instability, KRAS mutation, BRAF mutation, TP53 mutation, CpG island methylator phenotype, Wnt signaling, relapse-free survival, prognosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms, Female, France, Genetic Testing, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, RNA, Messenger, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Cluster Analysis, Chi-Square Distribution, Logistic Models, Proportional Hazards Models, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.